Shehata Islam, Hashim Ahmed, Elsaeidy Ahmed, Nair Anagha, Urits Ivan, Viswanath Omar, Kaye Alan D, Habib Marian
anesthesiology, Ain Shams University.
Ain Shams University.
Health Psychol Res. 2022 Oct 4;10(4):35848. doi: 10.52965/001c.35848. eCollection 2022.
For decades, chronic pain was managed with an almost conventional approach of using a wide range of analgesic spectrum, surgical approaches and complex interventional pain techniques to modulate or even interrupt pain pathways. These different approaches carry many pharmacological hazards together with the lack of efficacy and safety of many interventional and surgical management techniques for chronic pain have mandated searching for other effective therapies including alternative treatments. Cannabinoids are naturally occurring substances that are derived from Cannabis sativa L. The usage of cannabinoids and their related synthetic chemical compounds has emerged as a choice in the management of different chronic pain conditions is being evaluated, however, the efficacy is still not consistently established. In the present investigation, therefore, we discuss the different aspects related to cannabinoids and their implications in the management of chronic pain conditions. This review will also discuss the safety profile of the cannabinoids together with the legal considerations that hinder their use in different countries.
几十年来，慢性疼痛的治疗几乎采用传统方法，即使用广泛的镇痛药物、手术方法以及复杂的介入性疼痛技术来调节甚至中断疼痛传导通路。这些不同的方法存在许多药理学风险，而且许多慢性疼痛的介入性和手术管理技术缺乏有效性和安全性，这就促使人们寻找其他有效的治疗方法，包括替代疗法。大麻素是从大麻中天然提取的物质。大麻素及其相关合成化合物在不同慢性疼痛病症管理中的应用已成为一种选择，目前正在进行评估，然而，其疗效仍未得到一致证实。因此，在本研究中，我们讨论了与大麻素相关的不同方面及其在慢性疼痛病症管理中的意义。本综述还将讨论大麻素的安全性概况以及阻碍其在不同国家使用的法律考量因素。
